Bio-Rad, BioSource, GE, Eli Lilly, Agilent, Proteome Systems, NCI, ABI, Stratagene, Sidney Kimmel Cancer Center | GenomeWeb

Bio-Rad Buys Bigger Stake in BioSource
After Firm Rejected Earlier Acquisition Offer

After BioSource International rebuffed Bio-Rad's unsolicited $82 million acquisition offer last week (see BCW 4/14/2005), Bio-Rad this week said it has increased its ownership in the reagents company to 6.8 percent from 5 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.